| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Glycovir targets alpha-glucosidase-1, an enzyme involved in the processing of viral glycoproteins in the endoplasmic reticulum of host cells. By inhibiting this enzyme, the compound disrupts proper folding and trafficking of HIV envelope glycoproteins, thereby impairing viral infectivity and replication.
|
|---|---|
| ln Vitro |
In vitro, glycovir inhibits viral replication with an IC₅₀ range of 2-8 µM, comparable to the well-known antiviral drug Remdesivir. It has been studied for its antiviral effects against HIV, acting by inhibiting viral replication and entry into host cells. The compound demonstrates potent anti-HIV activity in cell-based assays.
|
| ln Vivo |
In vivo, glycovir has been used in trials investigating its use to treat HIV infection. As a prodrug, it is converted to its active form SC-48334 to exert antiviral effects. The compound has been evaluated in preclinical and clinical studies for HIV treatment.
|
| Enzyme Assay |
Alpha-glucosidase-1 inhibition assays are performed using microsomal membrane preparations or recombinant enzyme. The enzyme is incubated with test compound at various concentrations and a fluorogenic substrate. Inhibition is measured by detecting the decrease in fluorescent product formation. IC₅₀ values are calculated from dose-response curves. For antiviral activity, HIV-1-infected cells are treated with glycovir and viral replication is quantified by measuring p24 antigen levels or viral RNA by qRT-PCR.
|
| Cell Assay |
HIV-1-susceptible cell lines (e.g., MT-4 or CEM-SS cells) are cultured in RPMI-1640 medium with 10% FBS. Cells are infected with HIV-1 at a defined multiplicity of infection and treated with glycovir at various concentrations (typically 0.1-50 µM). After 3-7 days of culture, supernatant is collected for p24 antigen ELISA or viral RNA extraction for qRT-PCR. Cytotoxicity is assessed using MTT or CellTiter-Glo assays to determine the selectivity index.
|
| Animal Protocol |
In vivo efficacy studies are conducted in HIV-infected animal models or human clinical trials. Glycovir is administered orally or via other routes at specified doses. Pharmacokinetic parameters and antiviral efficacy are assessed by measuring viral load (HIV RNA levels) in blood. Safety and tolerability are monitored through clinical observations and laboratory tests.
|
| ADME/Pharmacokinetics |
Glycovir (SC-49483) is a prodrug with good oral bioavailability. Its molecular weight is 499.64, with density 1.09 g/cm³, boiling point 524°C at 760 mmHg, and LogP 3.887. The compound has been investigated in clinical trials for HIV infection. It is an alpha-glucosidase-1 inhibitor that targets viral glycoprotein processing in host cell endoplasmic reticulum.
|
| References |
:Pharm Res. 1995 Aug;12(8):1158-64.
|
| Additional Infomation |
Glicovir has been used in trials investigating its use to treat HIV infection.
Glycovir is a candidate anti-HIV agent that acts by interfering with viral glycoprotein processing. As a prodrug of SC-48334, it represents a class of antiviral agents targeting host cell enzymes rather than viral proteins directly, offering a potential mechanism to reduce viral resistance. The compound has been studied in clinical trials for HIV treatment. |
| Molecular Formula |
C26H45NO8
|
|---|---|
| Molecular Weight |
499.64
|
| Exact Mass |
499.315
|
| Elemental Analysis |
C, 62.50; H, 9.08; N, 2.80; O, 25.62
|
| CAS # |
131262-82-3
|
| Related CAS # |
131262-82-3;238075-09-7;
|
| PubChem CID |
60807
|
| Appearance |
Solid powder
|
| Density |
1.09g/cm3
|
| Boiling Point |
524ºC at 760mmHg
|
| Flash Point |
270.7ºC
|
| Vapour Pressure |
4.48E-11mmHg at 25°C
|
| Index of Refraction |
1.488
|
| LogP |
3.887
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
20
|
| Heavy Atom Count |
35
|
| Complexity |
668
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CCCCN1C[C@@H]([C@H]([C@@H]([C@H]1COC(=O)CCC)OC(=O)CCC)OC(=O)CCC)OC(=O)CCC
|
| InChi Key |
MKGDNVHZSCXBKR-KYVQNOJUSA-N
|
| InChi Code |
InChI=1S/C26H45NO8/c1-6-11-16-27-17-20(33-22(29)13-8-3)26(35-24(31)15-10-5)25(34-23(30)14-9-4)19(27)18-32-21(28)12-7-2/h19-20,25-26H,6-18H2,1-5H3/t19-,20+,25-,26-/m1/s1
|
| Chemical Name |
[(2R,3R,4R,5S)-3,4,5-tri(butanoyloxy)-1-butylpiperidin-2-yl]methyl butanoate
|
| Synonyms |
SC-49483 SC 49483 Glycovir
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0014 mL | 10.0072 mL | 20.0144 mL | |
| 5 mM | 0.4003 mL | 2.0014 mL | 4.0029 mL | |
| 10 mM | 0.2001 mL | 1.0007 mL | 2.0014 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
